SCHEMBL17144777

SCHEMBL17144777

O=C(O)c1ccnc(CN2CCn3ccnc3C2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 6/20 0.58
▸ KDM5C P41229 3/20 0.58
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ SCD O00767 1/20 0.39
▸ SCD5 Q86SK9 1/20 0.39
▸ JMJD6 Q6NYC1 1/20 0.39
▸ VNN1 O95497 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ KDM2B Q8NHM5 2/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ KDM5A P29375 5/20 0.37
▸ KDM5B Q9UGL1 5/20 0.37
▸ KDM6B O15054 2/20 0.37
▸ KDM4A O75164 2/20 0.37
▸ KDM2A Q9Y2K7 2/20 0.37
▸ KDM3A Q9Y4C1 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17144722 0.93 KDM4C (0.56) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL19741663 0.93 KDM4C (0.56) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL17144910 0.80 JMJD6 (0.42) KDM4CKDM5CKDM4EALDH1A1TSHR
SCHEMBL17145118 0.78 JMJD6 (0.46) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL15636461 0.77 KDM4C (0.76) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL2305288 0.77 KDM4C (0.76) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL28441622 0.77 KDM4C (0.71) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL17144975 0.77 KDM4C (0.48) KDM4CKDM5CKDM4EALDH1A1JMJD6
SCHEMBL16291774 0.76 KDM4C (0.74) KDM4CKDM5CKDM4EALDH1A1MAPT
SCHEMBL17144982 0.75 KDM4C (0.47) KDM4CKDM5CKDM4EALDH1A1KDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US claimed
EP-3126345-A1 INHIBITORS OF HISTONE DEMETHYLASES Gilead Sciences, Inc. (US) 2017-02-08 — — EP claimed
WO-2015153498-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS, APS (DK) 2015-10-08 — — WO claimed
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES KDM1B, KDM3A, KDM1A KDM4C 38/4885KDM5C 16/4885KDM4E 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback